An early-stage Biogen, but specialized in developing a novel Alzheimer's treatment.

Like a startup Eli Lilly, entirely focused on a breakthrough Alzheimer's drug candidate.

• ACU193: A humanized monoclonal antibody drug candidate in Phase I clinical trials, designed to target soluble amyloid-beta oligomers for the treatment of Alzheimer's disease.

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company. At this stage, the company is focused on the research, development, and clinical trials of its drug candidate ACU193. It does not currently have any approved products on the market for sale, and therefore, does not have major customers in the traditional sense of selling products or services.

Daniel O'Connell, Chief Executive Officer

Mr. O'Connell has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc. since December 2014. He has over 20 years of venture creation, venture investment, and start-up operations experience, with a focus on neuroscience companies. Under his leadership, Acumen transitioned from a privately-held, pre-clinical biotech company to a publicly-traded clinical-stage company. Mr. O'Connell previously co-founded and served as President and Chief Executive Officer of Functional Neuromodulation Ltd., a clinical-stage company developing deep brain stimulation therapies for Alzheimer's disease. He is also a founding member and former managing partner of NeuroVentures Capital, LLC, a firm involved in investing in emerging neuroscience companies. His involvement with Acumen began as a seed investor.

Matthew Zuga, Chief Financial Officer & Chief Business Officer

Mr. Zuga has served as Chief Financial Officer and Chief Business Officer of Acumen Pharmaceuticals since May 2021. From June 2020 through June 2021, he also served as Chief Financial Officer and Chief Operating Officer and a board member of HighCape Capital Acquisition Corp. Since October 2013, Mr. Zuga has been a partner of HighCape Capital, LLC. He was an advisor to Acumen from July 2019 through April 2021. Mr. Zuga currently serves on the board of directors of Aziyo Biologics, Inc. His background includes working with HighCape Capital, LLC and HighCape Capital Acquisition Corp., indicating a pattern of involvement with investment firms that back companies, which often include private equity firms.

Jim Doherty, PhD, President & Chief Development Officer

Dr. Doherty was appointed President and Chief Development Officer effective February 1, 2024. He brings decades of neuroscience-focused research and clinical development expertise, spanning from discovery through drug approval. Prior to joining Acumen, Dr. Doherty served as Chief Development Officer at Sage Therapeutics, where his team achieved U.S. Food and Drug Administration approvals for two treatments for postpartum depression, Zulresso and Zurzuvae. Before his tenure at Sage, he was the Director and Head of the Neuroscience Department for the Central Nervous System and Pain Innovative Medicines Unit of AstraZeneca Pharmaceuticals.

Eric Siemers, MD, Chief Medical Officer

Dr. Siemers joined Acumen as Chief Medical Officer in 2018 and has over 25 years of experience overseeing clinical trials for neurodegenerative diseases. From 1998, he was with Eli Lilly and Company, where he was responsible for several Alzheimer's compounds' clinical trials, including five Phase III studies. Before Lilly, Dr. Siemers founded and headed the Indiana University Movement Disorder Clinic. He was a founding member of the Alzheimer's Association Research Roundtable and served on the steering committee for the Alzheimer's Disease Neuroimaging Initiative.

Russell Barton, MS, Chief Operating Officer

Mr. Barton serves as the Chief Operating Officer of Acumen Pharmaceuticals.

1. Clinical Development and Regulatory Approval Risk: Acumen Pharmaceuticals' primary asset, ACU193, is in Phase I clinical trials for Alzheimer's disease. The success of the company is almost entirely dependent on the successful advancement of this single product candidate through extensive and costly clinical trials (Phase I, II, and III) and subsequent regulatory approval. A significant percentage of drug candidates fail at various stages of clinical development due to a lack of efficacy, safety concerns, or other issues. Failure to demonstrate the drug's safety and efficacy, or to obtain regulatory approval from agencies such as the FDA, would severely jeopardize the company's business prospects.

2. Competition and Market Acceptance Risk: The field of Alzheimer's disease research and treatment is highly competitive, with many large pharmaceutical companies and biotechnology firms actively developing therapies. Even if ACU193 successfully completes clinical trials and receives regulatory approval, it will face intense competition from other approved treatments (if any are available at that time) and other investigational drugs in various stages of development. There is no guarantee that ACU193, if approved, will achieve significant market acceptance or commercial success against existing or future competitors.

3. Dependence on a Single Product Candidate: Acumen Pharmaceuticals' business is currently focused exclusively on the development of ACU193. The company's future is therefore entirely reliant on the successful development, approval, and commercialization of this one drug candidate. The failure of ACU193 at any stage of development or commercialization would have a profound negative impact on the company, as there are no other pipeline assets mentioned to diversify its risk.

The addressable market for Acumen Pharmaceuticals' main product, ACU193, which targets Alzheimer's disease by selectively focusing on toxic soluble amyloid-beta oligomers, is part of the broader and rapidly expanding global Alzheimer's disease therapeutics market.

The global Alzheimer's therapeutics market was estimated to be approximately USD 6.49 billion in 2025 and is projected to reach around USD 33.62 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 20.06% from 2025 to 2034. Another estimate places the global market at USD 5.36 billion in 2024, anticipated to grow to US$ 31.04 billion by 2034, with a CAGR of 19.2% from 2025 to 2034. A separate report estimated the global market size at USD 13.10 billion in 2025, expected to grow to USD 23.19 billion by 2032, at a CAGR of 8.5% from 2025 to 2032.

North America is a significant region within this market, having dominated the global Alzheimer's therapeutics market with a share of 46.10% in 2024. In 2022, North America held over 40.79% of the market share. The U.S. Alzheimer's drugs market alone was valued at USD 1.62 billion in 2022 and is projected to grow. As of October 2023, the U.S. market for Alzheimer's disease treatment was approximately $2,623 million, with an expectation to grow to $9,553 million by 2028.

ACU193 is a humanized monoclonal antibody, and the anti-amyloid monoclonal antibodies segment is projected to grow at a 12.80% CAGR from 2025 to 2034. Disease-modifying therapies (DMTs), which include drugs targeting amyloid-beta, are expected to dominate the global Alzheimer's market, contributing 69.2% of the market by 2033.

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company primarily focused on developing its lead drug candidate, ACU193 (sabirnetug), for the treatment of Alzheimer's disease. As the company does not yet have commercialized products, its future revenue growth over the next 2-3 years will primarily be driven by key developmental milestones and strategic partnerships related to its pipeline.

Here are 3-5 expected drivers of future revenue growth for Acumen Pharmaceuticals:

1. Positive Topline Results from the ALTITUDE-AD Phase 2 Study: A critical driver for Acumen Pharmaceuticals is the successful readout of topline results from its Phase 2 ALTITUDE-AD study for sabirnetug (ACU193), which is anticipated in late 2026. Positive data demonstrating efficacy and safety could significantly de-risk the program, attract potential partners for further development and commercialization, or pave the way for a pivotal Phase 3 study.
2. Achievement of Milestone Payments from Strategic Partnerships: Acumen Pharmaceuticals has engaged in strategic collaborations, such as with JCR Pharmaceuticals for the development of an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease. Such partnerships include the potential for significant milestone payments (e.g., up to $555 million from the JCR collaboration), which would directly contribute to the company's revenue.
3. Advancement of ACU193 into Later-Stage Clinical Development: Following successful Phase 2 results, the progression of ACU193 into a pivotal Phase 3 clinical trial would be a major step towards potential market approval. This advancement would significantly enhance the drug's value and attractiveness for larger pharmaceutical partners, potentially leading to lucrative licensing agreements or co-development deals that include upfront payments and future royalties.
4. Development and Progression of Additional Formulations or Next-Generation Candidates: Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology and developing new AβO-targeting antibodies. Progress in these areas could broaden the market potential for ACU193 or lead to new product candidates, attracting further investment and potential partnership opportunities that could generate revenue through milestone payments or future licensing.

Capital Allocation Decisions for Acumen Pharmaceuticals (ABOS)

Share Issuance

• Acumen Pharmaceuticals completed its Initial Public Offering (IPO) on July 1, 2021, with shares initially priced at $20.10 each.
• The number of common shares outstanding significantly increased from 0 in March 2021 to approximately 60.57 million by August 2025.
• The company recorded proceeds from the issuance of common stock, net of issuance costs, amounting to $7.94 million for the three months ending March 31, 2024.

Inbound Investments

• Acumen Pharmaceuticals has a substantial institutional investor base, with 146 institutions collectively holding over 40 million shares.
• In November 2023, the company entered into a Loan and Security Agreement, securing a $50.0 million term loan facility, and initially borrowed $30.0 million.
• The company's business model relies on funding from investors, partnerships, and licensing agreements to generate revenue and support its R&D efforts.

Outbound Investments

• On July 15, 2025, Acumen Pharmaceuticals entered a strategic collaboration, option, and license agreement with JCR Pharmaceuticals, which includes an upfront payment and potential future option payments if Acumen exercises its rights to develop certain products.
• The company has a collaboration and license agreement with Halozyme, Inc. to develop a subcutaneous formulation of its drug candidate, Sabirnetug (ACU193).

Capital Expenditures

• Acumen Pharmaceuticals reported minimal traditional capital expenditures, with $0.000 million USD in the most recent quarter and -$88,000 in the last 12 months, indicating a focus away from significant physical asset purchases.
• The primary allocation of capital is towards research and development, with expenses rising to $62.4 million for the six months ended June 30, 2025, driven by costs associated with manufacturing, materials, and clinical trials for its lead drug candidate, ACU193.
• The company continues to invest in personnel and infrastructure to support its extensive research and development activities for advancing its clinical programs.